Zuclopenthixol

Evidence Level: L5

Predicted Indications: 9

Zuclopenthixol

Pharmacist Assessment Report

Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Zuclopenthixol is a thioxanthene antipsychotic, originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is based on the computational model only.

Quick Overview

Item	Content
Original Indication	Schizophrenia
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	0.9999
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, zuclopenthixol is a thioxanthene antipsychotic that antagonises dopamine D1/D2 receptors, with additional alpha-1 adrenergic and 5-HT2 receptor affinity. Its efficacy in schizophrenia is established.

No clear mechanistic link to the predicted indication has been identified. Retinal dystrophies are mostly monogenic disorders of photoreceptor or retinal pigment epithelium structure and function, and none of zuclopenthixol’s receptor activities addresses that pathology. The high TxGNN score reflects a TxGNN model (deep learning) prediction and should not be read as biological or clinical support.

Other high-ranking predictions were also reviewed (hydranencephaly, congenital disorder of glycosylation with defective fucosylation, Charcot-Marie-Tooth disease type 1G, several myopia entities, perisylvian polymicrogyria and atypical glycine encephalopathy). All are at evidence level L5 with no plausible mechanistic link and no trials or literature. The myopia entities have a speculative connection through retinal dopamine signalling, but dopamine antagonism would be expected to be unhelpful or counterproductive.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 8097E	Clopixol Depot	Oily I.M. injection 200 mg in 1 mL	Not listed in the data compiled for this report

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Some general points from the prediction review are worth noting. Zuclopenthixol’s CNS-depressant and seizure-threshold-lowering properties could be a concern in populations with encephalopathy or seizures. Antipsychotic-associated extrapyramidal symptoms could also complicate use in patients with neuropathies. No drug interaction records were found in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN model (deep learning) score, with no clinical trials, no literature and no plausible mechanistic link between dopamine/adrenergic/5-HT2 antagonism and retinal dystrophy pathology. A systemic antipsychotic is not justified for a largely monogenic retinal disorder without supporting evidence.

To proceed, the following is needed:

Mechanism of action data and a credible mechanistic rationale for retinal dystrophy
Preclinical or literature evidence supporting benefit in the predicted condition
Approved indication text and safety information (warnings, contraindications) from the TGA-approved Product Information
Route and formulation compatibility assessment (the only Australian product is a depot intramuscular injection)
A drug interaction and safety review before any further consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.